Depression is a prevalent mental health disorder, and the incidence of depression is expected to increase in the coming years. This trend is likely to drive the growth of the treatment-resistant depression market. Moreover, advances in medical research and the development of new therapies for the treatment of depression are expected to drive the growth of the treatment-resistant depression market. This includes new pharmacological therapies, as well as non-pharmacological therapies such as psychotherapy and brain stimulation techniques.
Furthermore, there is a growing awareness of mental health issues, including depression, and this is likely to increase the demand for effective treatments for depression, including treatment-resistant depression. Regulatory requirements for the approval of drugs for the treatment of depression are becoming increasingly stringent, and this is likely to limit the entry of new players in the market.
Global Treatment Resistant Depression Market was valued at US$ 1,180.0 Mn in 2022 and is expected to witness a CAGR of 3.4% during the forecast period (2022-2030).
Prominent Companies in the Treatment Resistant Depression Industry:
AbbVie Inc.:
1. AbbVie Inc. is a pharmaceutical company established in 2013 after being spun off from Abbott Laboratories. The company focuses on developing drugs for several therapeutic areas, including neurology, immunology, and oncology. In 2020, AbbVie announced the results of a phase 2 clinical trial for a drug called RINVOQ (upadacitinib) in patients with treatment-resistant depression. The trial showed that RINVOQ was effective in reducing depressive symptoms in patients who had not responded to other treatments. In 2021, AbbVie announced that it had entered into a collaboration with Resilience to develop a portfolio of drugs for mental health conditions, including treatment-resistant depression. The collaboration will focus on developing new treatments that target the root causes of these conditions.
Lupin:
2. Lupin is an Indian multinational pharmaceutical company established in 1968. The company develops and produces drugs for various therapeutic areas, including cardiovascular, diabetes, respiratory, and central nervous system disorders. In 2020, Lupin announced that it had received approval from the US FDA for its generic version of Buprenorphine Hydrochloride Sublingual Tablets, which are used to treat opioid addiction and also show potential for treating depression. Lupin is also involved in the development of drugs for depression. In 2020, the company announced that it had entered into a licensing agreement with MonoSol Rx for the development of a sublingual film for the treatment of depression. The film is designed to deliver a combination of drugs that target multiple pathways involved in depression.
Eli Lilly and Company:
3. Eli Lilly and Company is a global pharmaceutical company established in 1876. The company is known for developing drugs for diabetes, oncology, immunology, and neurodegeneration. Eli Lilly and Company has also been involved in developing treatments for depression and other mental health disorders. In 2020, Eli Lilly announced the results of a phase 3 clinical trial for its drug, Lasmiditan, which showed that it was effective in reducing the frequency of migraines in patients with treatment-resistant depression. Eli Lilly is also involved in the development of drugs that target the glutamate system for the treatment of depression. In 2020, the company announced the results of a phase 2 clinical trial for its drug, LY545694, which showed that it was effective in reducing depressive symptoms in patients with treatment-resistant depression.